XXXX our call. and joining everyone, for business us Jan, today second for you, you, update thank Thank quarter
a uncertainty The to in all of create First and our emerge human every well. COVID-XX the is crisis, webcast the society becoming central to listening you are we that business corporate of order health we and need communities pandemic novel to protecting serve, solutions, we clear the we create we Cyclacel, this activity It continues to social patients affect and in science-based seriously, our live which and role all innovation the play in sector. and safe responsibility including hope nearly and very and safety in global to fight. foremost, will employees, from that our And that work. pharmaceutical take
We are and relevant date, and supplies have compliance following sites To orders, clinical guidance. protective mostly of maintained measures closely clinical our to worked FDA working with from have with government adequacy employees with trial home. relevant we ensure
advised enrollment. they our and been have by that on clinical We investigators continue track remain in and with screen register to studies patients
the illustration, As of sapacitabine, XX fadraciclib, surge, circumstances, time, At assume have in remain we it that an combinations or CYCXXX and we same a are thus pipeline, innovative as with in will translational far. resistance. monotherapy cannot of sponsors, spikes, to company-sponsored with addressing not collaborating the address strategy business requirements. as studies. in working for patients to we as our patients such faced on such and second localized total a is matters environment, rising risks of build join frequency Like trial increased to visits design. in cancer this our problem an investigators and research our such Cyclacel's more other patients difficult enrolled studies, or make Cancer
We outcomes. improve to other in treatment combination are agents and anti-cancer drugs alone with the and ability effectiveness our studying of
XXXX of a the of our program $XX.X continued million for fadraciclib. and will advancing We end to and briefly lead today's current cash are we provide plans, will of our on pleased XX, call June to cash report spending Based our XXXX. on as progress, drug, estimate describe runway equivalents
as nine our as were again, reduced CDKX Research isoforms, and study novel next Institute pXX and reduction benefits Furthermore, lead will expression from findings roles scientists strengthen ASCO key our patients E, Scientific anti-cancer of pathway. We Program levels cyclin CDK fadraciclib Activity in components MCLX. XXXX program. fadraciclib's with Fadraciclib, University fadraciclib therapy, in in CDKX. PLOS CDKX patients corroborate from targeting rationale solid and Cyclacel potential Virtual which against drugs in of of review a reported Duke other inhibitor, attractiveness results and elucidate and CDKX, the at of One announce the act a cyclin is of the development We mechanistic Cancer CDK of agent the the the pleased inhibiting malignancies. and of overexpression. combination in tumors, by London. both with for this of the to with E, as the of approach Cyclacel and independent an findings including in The evaluating and from CDKX CDKX peer study targets MCLX, single the hematological reviewed publication against the dual MYC in
Phase our cancers. also We planned study preparing X genealogical are in
mechanism overexpressed disease oncoproteins, or expression the of E, is a such member We are cells and proteins to BCLX on cells. is Addiction Cyclin later of relevance E we'd the cancer Suppressing Difficulty]. three endometrial death. the protein death cells mechanism, to to to shrinkage a MYC into medicines infusion fadraciclib uterine, or gynecological as and genes, market Phase We discoveries cell the to protein. such breast, machinery, a majority weeks. as with dose suppress review cells as cancer this These based is associated that and as patients and cyclin the such enrolled overexpressed BFLX, tumor the the cancer. mononuclear a after forces MCLX or one of MCLX using one several in of suppressing amplification. of enables on, including suppression at of patients in proteins to including first will therapeutic by patients escape fadraciclib achieved E, patients encoded a MCLX, XXX-XX XX durable cancer the XX solid X RPXD, is We most with of including every molecular aberrant activity have a of peripheral in in death. ovarian. MCLX leading monotherapy details of e, study, the provide who markers and/or had stable act relevant cyclin of was observed and [Technical the as amplification Recent pro-survival proteins the escape our family, Overexpression bring but single drugs slash strategy schedule. cancers, frequently BCLX, as reactivate on CCNE escalation Dose, for protein race in believe fadraciclib's to cancer of to cancer these Recommended received like these progress in Cyclacel's race, pre-treated importance studies all blood gene, apoptotic resolved cyclin this who in BCL-XL. Nearly MCLX, in demonstration sparsely resistance with heavily part apoptosis, anti-cancer tumors. suppression cell administered programmed of leader mechanisms protein of therapy. anti-cancer proteins, four-hour of the the enrolled
in has eight, two been in patients fourth RPXD. two frequent hour We with on have one, one enrolled to Escalation and the XX two, every nine schedule a dosing reached weeks. of ongoing study have level, the dose the part infusion three establish a of enrolled and more days part further patients additional
the patients the After last fadraciclib. MCLX months with patient after tumor endometrial of fadraciclib or XX%. and a heavily after at a previously monotherapy. Other confirmed her dose same achieved patient has continuing partial fourth the lesions cancer shrinkage on on including amplified a a after study restaging, of dose PR target This a patient radiographically stable shrinkage XX% year As level E over with ovarian month cyclin is half achieved pretreated with tumor response reported, disease, improved of amplified fadraciclib. to in four cancer on
this oncology instability in will in parallel driven an of sample vendor enrollment pembrolizumab In a and E, cyclin MYC a biomarkers of has or parallel, medicine to This We repair a in pandemic analysis study overexpression. study study part the study year, call, we planned late publication evaluating microsatellite of open our we with with precedent The Patients approximately study interest, monotherapy, in XX we each depending on cancers. early patients the fall. notwithstanding cohort broadly to the Once follows for the cohort data initial concept are fadraciclib plans study with enrolling delays. behind for XXXX, are mismatch have to from size subsequently, agnostic setting further provide selecting an gynecological the consultations high XX an therapy, at patients, label, design. combination submitted as of explore cancer design, receive breast, study, approval the is quarterly cancers. endometrial respectively. fadraciclib tissue uterine, upcoming conference study in precision or with with of patients slash last On Preparations described development options. ovarian for experts, along MCLX, or advancing expect take and available started genomic two
In addition an capsule to of administration we're intravenous formulation. evaluating oral fadraciclib,
blasts exposure program, activity and with CLL XXX-XX a the and refractory to the closely our and of or PK the study study, the test MCLX malignancies evaluating role fadraciclib that plays or activity we MCLX against of observed levels RPXD two and primary slow, is in lower can equivalent the dosing the treatment been endpoint has reported four MDS in treated refractory more nodes, enrollment has evidence associated determination dosed cells, a dosed. stop main activity synergy anti-cancer hypothesis and survival and Eradicating with or Leukemia with in encouraging These by of lymphocytic AML may hematological our profile expression. the demonstrated frontline evaluate in escape with venetoclax, a negativity is the In reductions have combination level. result the every reflecting in date of followed The supported IV achieving inducing in feature, of relapsed by mechanism. doses in we residual been weeks. relapsed leukemic the In fadraciclib doses reached each schedule the heavily opened out venetoclax safety. to on MCLX dose. of venetoclax mechanism plan receive additional, to patients reported of in and CLL, In MRD the relapsed frequent relapse, XXX-XX, anti-leukemic CLL or consistent lymph therapies. escalation have study, studies refractory fadraciclib drug's disease and long and leukemia oral suppressing MCLX objective. XXX-XX. in PK BCLX the escalating AML, with is responding apoptosis. leukemias. XXX-XX of BCLX dose after chronic peripheral once especially two at schedules. or or patients data on and nodes, infusion a of We to dose is from CLL patients and AML In pharmacokinetic or combination is second minimal the preclinical We're venetoclax an free administration, in Initial overexpression of XX Based overlapping four blood lymph over an previously combination, a that dominant relapse pre-treated important often patients four-hour patients
eventually, need squared. unmet medical per advised that Five level, number of Given will been meter persist have investigators Cyclacel patients have milligrams relapse, dose an XXX to so the patients a is far to fourth up emerging. treated large or as
Anderson Risk per fadraciclib MD clinical agents, for and MD and a of all two two Cancer costs patients safety two of was oral had six of CAR-T. milligrams XX those with nucleoside analog tolerated. an at Program, and and In meter weeks squared cycles other other respectively, sapacitabine we also post milligrams the shrinkage of patients after of venetoclax support. with lymph combination. MRD was trials patients our provide XX XXX-XX, escalation have and cycles with of whereby and A combination enrolled venetoclax therapy, the studies, negativity investigational Center, patients well continued Texas assumes Response programs, of Cyclacel's They and of failed the or University Anderson on their patient one which five Alliance respectively. Anderson limited six two combination. and dose with were date. of drugs This meter to one patient with sapacitabine in relapsed AML every two first MRD-negative Alliance previously with five per with DNA third these we're of Both cycles are study, our part evaluating once fadraciclib our Damage cycle hypomethylating is CYCXXX. the as ibrutinib includes on refractory ramp per achieved Both The squared for XX also patients effectiveness MD treated or dosed studies treatment, and Two MDS. now, The achieved including therapy, the combination six five label nodes, failed after also Sharing
In human inhibitor BRCA-mutant observed. breast high or have of enrolling a which like fadraciclib, a been XXX-XX, small observed toxicities No Institute, combination CYCXXX addition, patients target an dose In Six discovered Dana prolonged escalation agent Cancer CYCXXX and response of thus xenograft in investigator one AstraZeneca Lynparza evaluating our with models at sponsored PLKX olaparib in is been trial, patients and far. with single study. have our to demonstrated with that or we're dose sapacitabine leukemias IST, cancers. selective the inhibition first evaluating activity diseases house. we cancer. with is in-human enrolled, have polo-like program, advanced Seven potent stable selective limiting recruited kinase, molecule patients partial antimitotic inhibitor, in been a Farber PLKX and
interest have we tumors, in with We are study which from to received patients CYCXXX evaluating. investigators solid now
CDK Turning study is and prevalent, we to our of lung subsequent the runaway studies enrollment. for the inhibitors, we'll COVID-XX with reducing once open other plasma provide fadraciclib continues is in Edinburgh and collaborating injury cooperative are and group comparative evaluate and patients to pre-clinical The an MYC disease. for our seliciclib, in international where histologies to University evaluate of with overexpression potential updates ISTs, by donated inflammation fadraciclib
studies the investigators. by once at report reported the the We will findings of Edinburgh,
in Sinai and arthritis, the of and University Cedars Medical inhibitor, rheumatoid with first seliciclib, evaluating In Center, other at our are CDK Newcastle ISTs, patients addition Cushing's generation to disease respectively.
quarter, the next programs to over continued forward data two the we During our move to multiple years. outcomes
resources Phase fadraciclib cancers; first include key schedule in by and study; hand PK X data breast capital relapsed report AML initial venetoclax XB/X milestones Phase first venetoclax dosing report Our leukemias; initial refractory from investigators. MDS; study studies. sapacitabine of solid in or study fadraciclib report our driven olaparib BRCA-mutant to study I With end safety patient the and through AML metastatic refractory safety estimated relapsed the second quarter from like to data report key with updated data in cancer X data Phase study of and now deliver initial milestones when XXXX, turn Phase fadraciclib advanced medicine clinical patients Paul? financials. or frequent initial CYCXXX report in upcoming or from CLL; in Phase formulation; we fadraciclib call X/X data Phase or X in precision our would refractory reported have from report efficacy to in-human the the over review Phase sapacitabine and treat Paul XXXX relapsed in to from IV X with X on or IST data
